Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02416271 · ClinicalTrials.gov registry record · Phase 4
The Forteo Alendronate Comparator Trial
A Phase 4 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 203
- Enrollment target
NCT02416271: Completed Phase 4 study, sponsored by Eli Lilly and Company.
NCT02416271 is a Phase 4 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 203 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (61% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02416271, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 203 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the effects of teriparatide with those of alendronate on spine bone mineral density (BMD) and other osteoporosis factors in postmenopausal women with osteoporosis.
Interventions
- DIETARY_SUPPLEMENT Vitamin D
- DRUG Teriparatide
- DRUG Alendronate
- DIETARY_SUPPLEMENT Calcium
- DRUG Placebo-Oral
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 203 participants |
| Start Date | 2001-04 |
| Est. Completion | 2003-05 |
| Phase | Phase 4 |
What the finished NCT02416271 record still lists
NCT02416271 is an interventional study that assigns participants to a tested intervention. The registered 203 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (61% lower).
The record links to 0 conditions, and to 5 interventions - of which Vitamin D is the first listed.
NCT02416271 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02416271 about?
NCT02416271 is a clinical study titled "The Forteo Alendronate Comparator Trial". The main purpose of this study is to evaluate the effects of teriparatide with those of alendronate on spine bone mineral density (BMD) and other osteoporosis factors in postmenopausal women with osteoporosis.
What is the current status of trial NCT02416271?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 203 participants. The study started on 2001-04. Estimated completion is 2003-05.
What interventions are being tested in trial NCT02416271?
The interventions under investigation include: Vitamin D (DIETARY_SUPPLEMENT), Teriparatide (DRUG), Alendronate (DRUG), Calcium (DIETARY_SUPPLEMENT), Placebo-Oral (DRUG).
Who is sponsoring clinical trial NCT02416271?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02416271's enrollment target sits among peer trials
203 403rd of 2000 higher than 1,597 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05652686 · 203 participants · Phase 1
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
- NCT06063122 · 203 participants · NA
Development of a Therapeutic Device to Improve Speech Sound Differentiation in Preterm Infants
- NCT07031245 · 203 participants · NA
Evidence-Based Quality Improvement to Reduce VA Primary Care Burnout
- NCT03481010 · 204 participants · NA
Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia